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Abstract
Introduction
Neuropathic pain (NP) can cause substantial suffering and, therefore, it must be diagnosed
and treated promptly. Diagnosis of NP can be difficult and if made by an expert pain physi-
cian is considered the gold standard, however where expert help may not be easily avail-
able, screening tools for NP can be used. The painDETECT questionnaire (PD-Q) is a
simple screening tool and has been widely used in several languages. We developed an
Arabic version of PD-Q and tested its validity and reliability.
Methods
The original PD-Q was translated into the Arabic language by a team of experts. The trans-
lated version of the PD-Q was administered to the study population, which included patients
having moderate to severe pain for at least three months. Reliability of the Arabic version
was evaluated by an intra-class-correlation coefficient (ICC) between pre- and post-mea-
sures and Cronbach’s α values. Validity was measured by receiver operating characteristic
(ROC) curve. Expert pain physician diagnosis was considered as the gold standard for com-
paring the diagnostic accuracy.
Results
A total of 375 patients were included in the study, of which 153 (40.8%) patients were
diagnosed with NP and 222 [59.2%] patients had nociceptive pain. The ICC between pre-
and post-PD-Q scale total scores for the overall sample, NP group, and NocP group was
0.970 (95% CI, 0.964–0.976), 0.963 (95% CI, 0.949–0.973), and 0.962 (95% CI, 0.951–
0.971), respectively. The Cronbach’s α values for the post-assessment measures in the
overall sample, NP group, and nociceptive pain group, were 0.764, 0.684, and 0.746,
respectively. The area under the ROC curve was 0.775 (95% CI, 0.725–0.825) for the PD-
Q total score.
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Conclusion
The Arabic version of the PD-Q showed good reliability and validity in the detection of NP
component in patients with chronic pain.
Introduction
The International Association for the Study of Pain (IASP) defines pain as “an unpleasant sen-
sory and emotional experience associated with actual or potential tissue damage or described
regarding such damage” [1]. The two main types of pain, neuropathic pain (NP) and nocicep-
tive pain (NocP), differ in their pathology and clinical presentation. While NP is caused by
activation of nociceptors as a result of direct damage to tissues, NocP occurs due to disease or
lesion of the somatosensory nervous system [2, 3]. Thus, the pain sensation in NP is without
any apparent external injury [4]. Clinically, NP can present with burning type continuous
pain, electric shock-like sensation, and mechanical allodynia. It is also characterized by hyper-
algesia, paresthesia, and dysesthesia [5]. NP component is usually found in conditions such as
back pain, diabetic polyneuropathy, post herpetic neuralgia, etc. [6, 7]. The pain is chronic and
can lead to substantial suffering by causing anxiety, depression, sleep deprivation, frequent vis-
its to the hospital, and reduced quality of life [8, 9]
Moreover, NP does not respond to conventional analgesics such as paracetamol and non-
steroidal anti-inflammatory drugs (NSAIDs). Instead, NP is treated with certain other agents
such as tricyclic antidepressants (amitriptyline, imipramine, clomipramine), serotonin-norepi-
nephrine reuptake inhibitors (duloxetine, venlafaxine), and antiepileptics (pregabalin, gaba-
pentin) [10]. Diagnosis of NP can be challenging, and diagnostic inaccuracy may lead to
inappropriate treatment. It is, therefore, of utmost importance that the type of pain is accu-
rately diagnosed.
Reaching the precise diagnosis of NP may be difficult especially in the primary care setting.
Based on the distinct features of NP that distinguish it from NocP, several screening tools have
been developed to help in the diagnosis [11]. While evaluation by an expert pain physician is
considered as a gold standard for diagnosis of NP, these tools can be very useful for initial
screening. Screening tools commonly used include the Leeds Assessment of Neuropathic
Symptoms and Signs (LANSS), the Neuropathic Pain Questionnaire (NPQ), painDETECT
questionnaire (PD-Q), and ID-Pain [12–15].
The PD-Q was first used in the German population in the year 2004. Since then, it has
become very popular and has been translated into several languages including Spanish, Swed-
ish, Dutch, Turkish, Japanese, and Korean [16–21]. More than 300,000 patients worldwide
have been assessed for NP using the PD-Q [4]. Although PD-Q has been widely used, Arabic
translation has not been developed and validated.
Patient access to care is different rural areas as compared to urban areas and different for
different socioeconomic statuses. Lack of trained personnel is also a burning issue. To date
there are no, regional guidelines for NeuP management, which are largely dependent on the
local settings. To raise awareness among healthcare practitioners about NeuP, and to provide
them a simple tool for its diagnosis to alleviate the suffering of the patients afflicted with
chronic pain due to neuropathological causes, in the Kingdom of Saudi Arabia, especially in
the remote areas where expert medical help is lacking. To address this unmet need, we devel-
oped an Arabic version of PD-Q and tested its validity and reliability.
Arabic version of painDETECT questionnaire
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Materials and methods
Study population
Adult patients attending any of the three clinics: pain management e diabetes and orthopedics
at a single tertiary hospital in Riyadh, King Fahad Medical City (KFMC) were included in the
study. Patients with moderate to severe NP or NocP pain (scoring 5 or higher on a 0–10
numerical rating scale) for a minimum of three months were included. Patients with the pain
of unknown origin, mixed-type pain, and diffuse pain which includes fibromyalgia syndrome,
myofascial pain, complex regional pain syndrome, cancer pain, and headaches wereexcluded.
Patients with substance abuse, chronic alcoholism, severe depression, and those incapable of
understanding the questionnaire were excluded [22].
The study was approved by the Institutional Review Board at KFMC, Riyadh, Saudi Arabia.
Written informed consent was obtained from the participants who met inclusion criteria and
agreed to participate in the study.
Recruitment
The study participants were randomly approached and invited to participate in this study by
the research team over a period of one year from March 2016 to March 2017.
Translation of the questionnaire
The adaptation procedure was monitored by an expert panel including two specialists in pain
management, an expert in research methodology, an expert in clinical research, and an expert
in linguistics. The international guidelines for cross-cultural adaptation of health question-
naires and diagnostic tests were followed. An internationally-accepted translation methodol-
ogy was used by a well-established linguistic validation process [23, 24].
Two bilingual translators, with Arabic mother tongue, translated the questionnaire to the
Arabic language. While one of the translators was informed about the questionnaire and its
applications, the other had no information about the questionnaire. Each translator indepen-
dently produced a translated version. The two versions were then combined into a single
questionnaire. This was followed by backward translation to English by two native English
speakers who had no knowledge of the original version. A meeting was then held between the
experts and the two translator teams to discuss the original and translated versions. The expert
committee consolidated all the versions and developed the pre-final version for pre-testing.
The pre-final version was administered to a sample of 30 patients as a part of pre-testing. Each
patient was asked to fill-in the form and was then interviewed about his/her understanding of
each item of the questionnaire and the corresponding response.
Study design
The study population was divided into two groups. The first group included patients diag-
nosed with NP by a pain specialist in pain clinics as per the guidelines established by the IASP
[3]. The second study group included patients with NocP.
The same investigator administered the Arabic version of the PD-Q to the study population
twice (pre-clinic visit and post clinic visit) within a gap of two to four hours (S1 Arabic version
of the painDETECT questionnaire).
Description of PD-Q
The PD-Q is simple, self-administered, useful screening questionnaire that allows detecting
NP component in patients with chronic pain. The PD-Q consists of four main sections. The
Arabic version of painDETECT questionnaire
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first section contains three items with 11-point Likert scale format with anchor terms in the
scale ends (0 = no pain, 10 = maximum pain), accompanied by a color grading scale represent-
ing pain intensity in analog format. These items assess the intensity of pain at the time of
administration of the scale, and maximum pain intensity and average pain during preceding 4
weeks. The first section is used to diagnose the presence of pain and is not included in the
questionnaire scoring. In the second section, patients are asked to mark one of the four graphs
that best describe their pain course patterns. The possible patterns and their scores are deter-
mined as follows: persistent pain with slight fluctuations (0 points), persistent pain with pain
attacks (−1 point), pain attacks without pain between them (1 point), and pain attacks with
pain between them (1 point). The third section includes a sensory map representing homuncu-
lus along with questions designed to mark the pain zone, a dichotomous item about the
presence of radiating pain and showing the direction of radiating pain with an arrow. The pos-
itive answer about the presence of radiating pain is scored with two points. In the last section,
there are seven Likert type items asking about the intensity of the sensation marked over the
homunculus. These items are scored with a 6-point Likert format, with corresponding ordinal
anchor terms (0 = never, 1 = hardly noticed, 2 = slightly, 3 = moderately, 4 = strongly, 5 = very
strongly). These Likert-type items enquire about the following sensations: burning, tingling or
prickling, allodynia, pain attacks, temperature evoked pain, numbness, and pressure-evoked
pain. This last section provides scores between 0 and 35 points. The final score is obtained
summing up the scores of the last three sections with a total score of −1 to 38. Two cutoff val-
ues are used by the developer of PD-Q for the presence of NP. Scores12 state that an NP
component is unlikely and scores19 indicate that neuropathic component is very likely to be
present. Scores between 12 and 19 suggest that the result is unclear [15].
Sample size estimation
The sample size was calculated assuming a significance level of α = 0.05 and prevalence of 41%
with power = 0.95 and maximum difference = 0.5. The sample size that is needed to validate
the questionnaire for the two groups was 376 patients.
Statistical analysis
Socio-demographic and clinical characteristics of patients were summarized for the whole
sample (NP group and NocP group) using frequency (%) for categorical variables and mean
(standard deviation, SD) for continuous variables. For continuous variables, normality was
assessed using Shapiro Wilk test and histograms. The socio-demographic and clinical charac-
teristics were compared between the two groups using a chi-square test for categorical vari-
ables and t-test or Mann Whitney’s U test for continuous variables.
Examining reliability of PD-Q. The PD-Q responses were collected in two sessions, one
pre-clinic visit and the other post- clinic visit. For the test re-test reliability of the items of
PD-Q and its total scale score, intra-class-correlation coefficient (ICC) between pre- and post-
measures were computed. For the pre- and post- clinic visits, correlation of the items of PD-Q
with the total scale scores were assessed using Spearman correlation coefficients. Cronbach’s α
for the pre- and post-measures of the items of PD-Q were computed to examine the internal
consistency. All the above analyses were performed for the whole sample and also separately
for the two study groups.
Assessing validity of PD-Q. Initially, median (interquartile range) of the total scores for
PD-Q were computed and Mann Whitney’s U test was used to compare the scores between
NP and NocP groups. Thereafter, to assess the discriminant validity of PD-Q in identifying the
NP, we used receiver operating characteristics curve (ROC) analyses. A binary variable with a
Arabic version of painDETECT questionnaire
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physician diagnosis of (NP = 1) versus (NocP = 0) was created. Physician diagnosis of neuro-
pathic pain was carried out before the questionnaire was completed by the participants and the
physicians were blinded to the responses on the questionnaires. In the logistic regression anal-
ysis, we used the physician diagnosis of neuropathic pain (a binary dependent variable) to
assess how the total score of PD-Q scale predicts the physician diagnosis. This analysis assessed
the validity of PD-Q by establishinga corroboration between physician diagnosis and question-
naire diagnosis for. Next, ith th binary variable, a ROC curve analyss was conducted for the
total scale scores of PD-Q. concerning for each cut-off-point of the scores, sensitivity, specific-
ity, correctly classified, positive likelihood ratio, negative likelihood ratio, was also calculated.
In this analysis, using Youden’ s index [25], the best cut-off value of the scales total scores were
determined. For the cut-off-value, the area under the ROC curve (95% CI) was computed,
which determined the discriminant validity (diagnostic ability) of the total scores. All these
analyses were separately performed for the pre and post-measure of the scales.
A statistical significance level of p<0.05 was used to reject the null hypothesis. The analyses
were conducted using statistical software of SPSS software version 17.0 (Chicago, IL, USA)
and Stata version 12 (StataCorp, Texas USA).
Results
A total of 375 patients were included in the study. Expert pain physicians diagnosed NP in 153
(40.8%) patients and NocP in 222 (59.2%) patients. The mean age of patients in the NP and
NocP groups was similar; however, the range was broader in patients with NocP (NP: 48.4±12.0
years [range, 21–71 years]; NocP: 48.9±14.5 years [range, 18–87 years]). Use of medication, dia-
betes, and heart disease were significantly more common in patients with NP. The duration of
pain was more in patients with NP (Table 1).
Paracetamol was the most common painkiller used in both NP (n = 71; 46.4%) and NocP
(n = 56; 25.2%) groups. Paracetamol was followed by meloxicam (NP: n = 35, 22.9%; NocP:
n = 34, 15.3%), and diclofenac sodium (NP: n = 35; 22.9%; NocP: n = 40; 18.0%) in both the
groups.
NP was most commonly seen in patients with low back pain/referred pain (74 [48.4%]),
and NocP was most commonly seen in patients with osteoarthritis (111 [50.0%]) (Fig 1).
Reliability of the PD-Q scale
There was a high level of test-re-test reliability for the items of the PD-Q scale in the overall
sample and the two study groups. The ICC between pre- and post-PD-Q scale total scores for
the overall sample, NP group, and NocP group was 0.970 (95% CI, 0.964–0.976), 0.963 (95%
CI, 0.949–0.973), and 0.962 (95% CI, 0.951–0.971), respectively. For the measures of the scale
in the post clinic visit, the Cronbach’s α values were 0.764, 0.684, and 0.746, in the overall sam-
ple, in NP group, and in the NocP group, respectively. For the pre-clinic visit measures of the
items of the PD-Q scale, a similar level of internal consistency was observed (Table 2).
The total scores for both pre-clinic visit and post clinic visit on the fourth section of the
PD-Q scale, which includes seven items were evaluated using the Spearman rank correlation
co-efficient, a significant (moderate to high) correlation between the total score and each item
of the scale was observed (Table 3).
Validity of the PD-Q scale
Considering the diagnosis as NP or NocP by a pain physician as the gold standard, when the
discriminant validity was examined using the receiving operating characteristics (ROC) curve
Arabic version of painDETECT questionnaire
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Table 1. Demographic and clinical characteristics of patients in neuropathic and nociceptive pain groups.
Variables Neuropathic pain(N = 153) Nociceptive pain(N = 222) p-value
Male, n (%) 51 (33.3) 58 (26.1) 0.131
Education Level, n (%) 77 (50.3) 133 (59.9)
High school and above 0.066
Occupation, n (%)
Employed vs. Unemployed 49 (32.0) 46 (20.7) 0.016
Marital Status, n (%)
Married 136 (88.9) 176 (79.3) 0.012
Single 13 (8.5) 24 (10.8)
Widow/Divorced 4 (2.6) 22 (9.9)
Medication use, n (%) 126 (82.4) 119 (53.6) <0.001
Diabetes mellitus, n (%) 60 (39.2) 65 (29.3) 0.045
Hypertension, n (%) 54 (35.3) 62 (27.9) 0.129
Liver disease, n (%) 6 (3.9) 3 (1.4) 0.168
Heart disease, n (%) 21 (13.7) 15 (6.8) 0.024
Lung disease, n (%) 8 (5.2) 6 (2.7) 0.205
Kidney disease, n (%) 8 (5.2) 10 (4.5) 0.747
Physical exercise, n (%) 44 (28.8) 41 (18.6) 0.021
Age (years), mean (SD) 48.4 (12.0) 48.9 (14.5) 0.721
Height (cm), mean (SD) 160.5 (10.3) 158.3 (9.2) 0.045
Weight (kg), mean (SD) 82.0 (17.1) 78.9 (18.5) 0.138
Body mass index (kg/m2), mean (SD) 32.0 (7.1) 31.6 (7.7) 0.665
Duration of pain (month), mean [Min -Max] 48 [24–84] 24 [12–48] 0.002
Significant odds ratios (OR) are in bold.
https://doi.org/10.1371/journal.pone.0194358.t001
Fig 1. Etiology of pain in the two study groups.
https://doi.org/10.1371/journal.pone.0194358.g001
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analyses, the area under the ROC curve was estimated to be 0.775 (95% CI, 0.725–0.825) for
the PD-Q total score (Fig 2).
The adjusted odds ratios of the clinical diagnosis of neuropathic pain for per unit increase
in the total score PD-Q scale was 1.15 (95% CI, 1.10–1.20; P<0.001) (Table 4). The final score
is obtained summing up the scores of the last three sections with a total score of −1 to 38. Two
cutoff values are used by the developer of PD-Q for the presence of NP. Scores12 state that a
NP component is unlikely and scores19 indicate that neuropathic component is very likely
to be present. Scores between 12 and 19 suggest that the result is unclear. The area under the
ROC curve was 0.775 (95% CI, 0.725–0.825) for the PD-Q total score. Further discriminant
statistics (i.e., percent sensitivity, specificity, correct classification, positive and negative likeli-
hood ratio) for each of the possible cut-off values are presented in Table 5. For example, for
Table 2. Test-re-test reliability: Agreement between pre- and post-clinic visits of PD-Q response and its internal consistency.
Items of the PD-Q Overall sample Neuropathic pain Nociceptive pain
Agreement n
(%)
ICC (95% CI) Agreement n
(%)
ICC (95% CI) Agreement n
(%)
ICC (95% CI)
How would you assess your pain now, at this moment? 85.6 0.971 (0.964–
0.976)
83.0 0.973 (0.962–
0.980)
87.4 0.969 (0.960–
0.976)
How strong was the strongest pain during the past 4 weeks? 90.7 0.985 (0.982–
0.988)
88.9 0.993 (0.991–
0.995)
91.9 0.979 (0.972–
0.984)
How strong was the pain during the past 4 weeks on average? 84.8 0.960 (0.951–
0.967)
81.1 0.931 (0.905–
0.950)
87.4 0.977 (0.969–
0.982)
Mark the picture that best describes the course of your pain 93.3 0.909 (0.888–
0.925)
92.2 0.905 (0.869–
0.931)
94.1 0.913 (0.887–
0.933)
Does your pain radiate to other regions of your body? 96.3 0.961 (0.952-
0.968)
98.0 0.965 (0.952–
0.974)
95.1 0.945 (0.928–
0.958)
Do you suffer from a burning sensation (e.g., stinging nettles) in
the marked areas?
89.6 0.943(0.931–
0.954)
85.0 0.942 (0.920–
0.958)
92.8 0.933 (0.913–
0.949)
Do you have a tingling or prickling sensation in the area of your
pain (like crawling ants or electrical tingling)?
85.3 0.945 (0.933–
0.955)
79.7 0.914 (0.882–
0.937)
89.2 0.961 (0.949–
0.970)
Is light touching (clothing, a blanket) in this area painful? 91.2 0.937 (0.922–
0.948)
84.3 0.924 (0.896–
0.945)
96.0 0.947 (0.931–
0.959)
Do you have sudden pain attacks in the area of your pain, like
electric shocks?
89.9 0.958 (0.948–
0.965)
88.2 0.966 (0.954–
0.976)
91.0 0.940 (0.921–
0.954)
Is cold or heat (bath water) in this area occasionally painful? 86.9 0.920 (0.902–
0.934)
79.1 0.898 (0.860–
0.926)
92.3 0.936 (0.917–
0.951)
Do you suffer from a sensation of numbness in the areas that you
marked?
84.8 0.948 (0.936–
0.957)
80.4 0.919 (0.888–
0.941)
87.8 0.953 (0.939–
0.964)
Does slight pressure in this area, e.g., with a finger, trigger pain 89.0 0.957 (0.947–
0.965)
87.6 0.955 (0.938–
0.967)
90.1 0.959 (0.947–
0.969)
Total scale score: - 0.970 (0.964–
0.976)
- 0.963 (0.949–
0.973)
- 0.962 (0.951–
0.971)
Consistency of the above 7 items of pain scale Cronbach’s α Cronbach’s α Cronbach’s α
Pre-clinic visit 0.575 0.518 0.505
Post-clinic visit 0.614 0.528 0.536
Consistency of all 12 items of the PD-Q
Pre-clinic visit 0.746 0.673 0.737
Post-clinic visit 0.764 0.684 0.746
Agreement: Observed agreement (%) of the items of PD-Q between pre- and post-clinic visits.
ICC (95% CI): Intra class correlation coefficient (95% confidence interval) for examining test re-test reliability of each items of the PD-Q scale and its total score
(continuous variables).
Cronbach’s α (alpha): Coefficient used to examine internal consistency of the PD-Q scale.
https://doi.org/10.1371/journal.pone.0194358.t002
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the cut-off value of total score 16, the sensitivity was 75.2%, specificity was 73.4%, the correct
classification was 74.1%, positive likelihood ratio was 2.828, and negative likelihood ratio was
0.338.
Discussion
In this study, the most common agent used for pain, irrespective of the pain type, was paracet-
amol followed by NSAIDs. This may mean that patients with NP either had no pain relief or
Table 3. Spearman rank correlation co-efficient total score for PD-Q scale with each of its items.
Total score for PD-Q scale
Items of PD-Q scale Pre-assessment Post-assessment
Overall sample
(n = 375)
Neuropathic pain
(n = 153)
Nociceptive pain
(n = 222)
Overall sample
(n = 375)
Neuropathic pain
(n = 153)
Nociceptive pain
(n = 222)
Do you suffer from a burning sensation (e.g.,
stinging nettles) in the marked areas?
0.592 0.532 0.551 0.618 0.552 0.537
Do you have a tingling or prickling sensation in
the area of your pain (like crawling ants or
electrical tingling)?
0.493 0.610 0.409 0.494 0.574 0.408
Is light touching (clothing, a blanket) in this area
painful?
0.465 0.437 0.432 0.496 0.456 0.449
Do you have sudden pain attacks in the area of
your pain, like electric shocks?
0.636 0.596 0.579 0.642 0.592 0.580
Is cold or heat (bath water) in this area
occasionally painful?
0.444 0.395 0.434 0.465 0.407 0.421
Do you suffer from a sensation of numbness in
the areas that you marked?
0.620 0.446 0.561 0.638 0.455 0.560
Does slight pressure in this area, e.g., with a
finger, trigger pain
0.334 0.443 0.333 0.354 0.445 0.374
All correlations coefficients were statistically significant at p<0.001
https://doi.org/10.1371/journal.pone.0194358.t003
Fig 2. ROC curve analysis: Plot of sensitivity versus 1-specificity (PD-Q scale).
https://doi.org/10.1371/journal.pone.0194358.g002
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had only partial relief, as they were not receiving appropriate treatment. If the diagnosis of NP
is made correctly early on, appropriate treatment can be instituted at primary care health facil-
ity and patients can benefit from it. A pilot study conducted by Hassan et al. from 10 centers in
the Middle East Region in 2004 puts the prevalence of NP as 41% in the chronic low back pain
patients and NocP as 59% [26]. In a prospective, multicenter, epidemiological study was con-
ducted to assess the prevalence of NP among adults with lower back pain in the Arabian Gulf
region. Out of 1134 patients, 628 (55%) patients were classified as having NP [27].
To achieve an accurate diagnosis, assessment by an expert pain physician including meticu-
lous history, clinical examination, and neurological evaluation must be carried out [28, 29]. It
has been suggested that the diagnosis of NP component is missed in a substantial number of
patients with pain [30]. In resource-challenged settings like in KSA where there is a lack of
expertise in primary care level due to non-availability of avenues for in-service training and
skill expansion of health care providers [31], screening tools such as the PD-Q can prove to be
extremely useful. The strength of PD-Q also lies in its simplicity and ease of use. This tool is
very convenient and can be easily administered by anyone without having to rely on a pain
expert.
The original version of the PD-Q, which was evaluated in a large population of about 8000
subjects, demonstrated high sensitivity, specificity, and positive predictive accuracy. This
screening tool can be used in primary care settings worldwide only if it is translated and
adapted for local use and tested for psychometric properties. Several translations of the PD-Q
have been developed and assessed in the corresponding local populations [16–21].
In this study, the first important step was a translation of the original version to the Arabic
language. The translation which was done as per the standard textbook Arabic language
understandable by most of the Arabic speakers and was not limited to the Saudi dialect only. A
panel of experts was employed to ensure that the translation and adaptation was done as per
internationally accepted norms. Additionally, the prefinal version was tested on a sample pop-
ulation before administering it to the study population. Expert pain physicians were involved
at several stages.
The demographics of both study groups including age, gender, occupation, and level of
education were fairly balanced indicating that there was no difference in the level of under-
standing of the questionnaires between the groups. The Arabic version of the PD-Q showed
good psychometric properties. Stability of the PD-Q over time (i.e., the test-retest reliability)
was excellent. The test-retest reliability was similar to previous studies [16, 17]. The ICC value
of the Spanish version was reported as similar to that of the Turkish version [16, 17]. Further,
Table 4. Logistic regression models to adjust the effect of total scale score in predicting the physician diagnosis of
neuropathic pain.
Variables PD-Q scale
OR (95% CI) p-values
Total scores 1.15 (1.10, 1.20) <0.001
Employed vs. Unemployed 2.44 (1.24, 4.79) 0.009
Marital Status 0.47 (0.28, 0.82) 0.007
Medication use 0.30 (0.16, 0.57) 0.000
Diabetes mellitus 0.72 (0.39, 1.35) 0.306
Heart disease 0.54 (0.21, 1.42) 0.214
Physical exercise 0.37 (0.19, 0.73) 0.004
Height (cm) 1.03 (1.00, 1.06) 0.070
Duration of Pain (month) 1.01 (1.00, 1.01) 0.115
https://doi.org/10.1371/journal.pone.0194358.t004
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internal consistency achieved for the total score in this study (Cronbach’s α = 0.764) was close
to the value attained by the Turkish version (Cronbach’s α = 0.81) of the PD-Q [17], and also
comparable to the original (Cronbach’s α = 0.83) and Spanish versions (Cronbach’s α = 0.86)
[15, 16]. In this study, when the internal consistency of all the 12 items of the PD-Q scale was
Table 5. Discriminative characteristics of the total score for PD-Q scale in identifying patients with neuropathic pain versus nociceptive pain (ROC curve analysis).
Cut point Sensitivity (%) Specificity (%) Correctly classified (%) LR+ LR-
( -1) 100.0 0.0 40.8 1.000
( 0) 100.0 0.5 41.1 1.005 0.000
( 2) 100.0 0.9 41.3 1.009 0.000
( 3) 100.0 3.2 42.7 1.033 0.000
( 4) 100.0 4.5 43.5 1.047 0.000
( 5) 97.4 6.8 43.7 1.044 0.387
( 6) 97.4 9.5 45.3 1.076 0.276
( 7) 94.8 13.1 46.4 1.090 0.400
( 8) 93.5 17.1 48.3 1.128 0.382
( 9) 91.5 22.5 50.7 1.181 0.377
( 10) 89.5 29.3 53.9 1.266 0.357
( 11) 86.9 41.4 60.0 1.485 0.315
( 12) 86.3 47.8 63.5 1.651 0.288
( 13) 84.3 58.1 68.8 2.013 0.270
( 14) 79.1 66.2 71.5 2.341 0.316
( 15) 76.5 68.0 71.5 2.391 0.346
( 16) 75.2 73.4 74.1 2.828 0.338
( 17) 72.6 77.0 75.2 3.158 0.356
( 18) 69.9 79.3 75.5 3.375 0.379
( 19) 67.3 81.1 75.5 3.558 0.403
( 20) 62.8 83.8 75.2 3.869 0.445
( 21) 57.5 86.9 74.9 4.403 0.489
( 22) 47.7 87.8 71.5 3.923 0.595
( 23) 45.1 88.7 70.9 4.005 0.619
( 24) 37.9 90.5 69.1 4.008 0.686
( 25) 34.0 91.9 68.3 4.192 0.718
( 26) 29.4 93.2 67.2 4.353 0.757
( 27) 21.6 94.1 64.5 3.683 0.833
( 28) 15.7 94.1 62.1 2.679 0.896
( 29) 13.7 96.0 62.4 3.386 0.899
( 30) 11.1 97.8 62.4 4.933 0.909
( 31) 10.5 98.7 62.7 7.739 0.908
( 32) 7.2 99.6 61.9 15.961 0.932
( 33) 5.2 99.6 61.1 11.608 0.952
( 34) 4.6 99.6 60.8 10.157 0.959
( 36) 2.6 99.6 60.0 5.804 0.978
(> 36) 0.0 100.0 59.2 1.000
Area under receiving operating characteristics (ROC) curve (95% CI) = 0.775 (0.725–0.825)
LR+: Positive likelihood ratio
LR-: Negative likelihood ratio
Cut-point: cut-off-value of the PD-Q total scale score.
https://doi.org/10.1371/journal.pone.0194358.t005
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assessed, it was in an acceptable range. The discriminant validity of the Arabic PD-Q version
was also good for NP versus NocP. Furthermore, the results of sensitivity, specificity, and cor-
rect classification for NP versus NocP were similar to those obtained in other studies [15, 16].
Hence, the Arabic version of PD-Q is reliable and valid scale for detecting NP in the Arabic
population. Especially in remote areas where expert help may not be available, the PD-Q can
be a real boon. It can serve as a powerful tool for initial screening of patients with pain.
Our study also had some limitations. This was a single tertiary hospital study as patients
from multiple centers could not be included due to logistic reasons.
Conclusion
In summary, we developed the Arabic version of the PD-Q and tested its psychometric proper-
ties. The Arabic version of PD-Q demonstrated good reliability and validity. A large-scale
study in the Arabic population is required to confirm the results of this study further and fur-
ther affirm the validity and reliability of the Arabic version of the PD-Q.
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